Trials / Completed
CompletedNCT05461430
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 72 (actual)
- Sponsor
- Travera Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, core needle biopsies, fine needle aspirates, or resections.
Conditions
- Pleural Effusion, Malignant
- Ascites, Malignant
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Renal Cell
- Carcinoma, Renal
- Carcinoma, Small Cell
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Pancreatic Ductal
- Carcinoma, Neuroendocrine
- Carcinoma, Thymic
- Carcinoma, Pancreatic
- Carcinoma Breast
- Carcinoma, Ovarian
- Carcinoma Bladder
- Carcinoma of Unknown Primary
- Carcinoma of the Head and Neck
- Carcinoma of the Oropharynx
- Carcinoma of the Larynx
- Carcinoma of the Bladder
- Carcinoma of Esophagus
- Carcinoma of the Nasopharynx
- Carcinoma of the Penis
- Carcinoma of the Cervix
- Carcinoma of the Anus
- Carcinoma of the Vulva
- Carcinoma of the Appendix
- Carcinoma of the Oral Cavity
- Cholangiocarcinoma
- Melanoma
- Mesothelioma
- Pancreatic Cancer
Timeline
- Start date
- 2022-07-15
- Primary completion
- 2026-03-23
- Completion
- 2026-03-23
- First posted
- 2022-07-18
- Last updated
- 2026-04-13
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05461430. Inclusion in this directory is not an endorsement.